Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Study Using M6620 (VX-970) An ATR Inhibitor to Treat Solid Tumors
Printer Friendly Page Study Using M6620 (VX-970) An ATR Inhibitor to Treat Solid Tumors

Study Using M6620 (VX-970) An ATR Inhibitor to Treat Solid Tumors

Clinicaltrials.gov identifier:
NCT03718091

Treatment

Study Contact Information:

Gregory M Cote, MD, PhD by phone: 617-724-4000 or by email


A Non-Randomized Phase II Research Study of M6620 (VX-970) in Selected Solid Tumors to Inhibit the ATR Enzyme.

About the Study

This clinical trial is studying how well M6620 works in treating patients with advanced . M6620 is a drug designed to block the ATR enzyme. ATR repairs damaged . In cancer, ATR may protect the cancer cells by helping them repair damage. Blocking ATR may keep cancers from repairing their damaged DNA; slowing the growth of, or killing cancer cells. The study is open to people with advanced and a , or mutation. The study will be recruiting people with different types of cancer, including people with advanced and a , or mutation. 

UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.

Type of Study

  • This is a , study.  All patients who enroll in the trial will receive the study medication.

What the Study Entails

  • Participants will receive M6620 intravenously (IV) over 60 minutes on Days 1, 4, 8, 11, 15, 18, 22, and 25 on a 28-day cycle
  • This cycles repeats every 28 days in the absence of disease progression
  • After 16 weeks (4 cycles), patients may receive M6620 weekly on days 1, 8, 15, and 22
  • Undergo on-treatment biopsy at Day 15

Study Locations

The following are participating institutions:

  • Massachusetts
    • Boston: Dana-Farber Cancer Institute
      • Contact Geoffrey I. Shapiro, MD by email 
    • Boston: Beth Israel Deaconess Medical Center 
      • Contact Glen Weiss, MD by email
    • Boston: Massachusetts General Hospital Cancer Center:
      • Contact Gregory M. Cote, MD, PhD, by phone: 617-724-4000 or by email
    • Boston: Boston Children Hospital:
      • Contact Katherine Janeway, MD by email 
This Study is Open To:

UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.

This Study is Not Open To:

UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.